Skip to main content
α
中文
Back to research

JD Health (6618.HK) stock analysis · Nov 2026

Updated regularlyHong Kong stockChina healthcare
Last price HK$42.84P/E (TTM) 15.0 · Next earnings 2027-03-04Updated November 10, 2026

At a glance

The most concerning issue in the current market is: whether JD Health's stock price can continue to increase volume and effectively stabilize at $44.10 at the critical point before breaking through the 200-day moving average, thereby establishing a medium-term upward trend.

Key research points

  • Technical bullish signals continue to appear: The MACD indicator value reached 0.638 and the histogram rose steadily. The fast and slow lines maintained the golden cross state, showing that the upward momentum is still accumulating.
  • The price has departed from the middle track and is significantly higher: The closing price at the time of writing ($43.00) is about 15.1% higher than the 20-day moving average ($37.34), and is near the upper track of the Bollinger Band, reflecting optimistic market sentiment but the risk of short-term overbought.
  • Key Resistance Level Approaching: The 200-day moving average ($44.10) forms the core pressure, only $1.10 away from the closing price at the time of writing. If it cannot break through, it will face callback pressure.
  • The support level structure is clear: $42.70 is the recent low, and $36.50 is the 50-day moving average. The two together form a phased support area, buffering short-term fluctuations.
  • RSI has entered the strong range: The latest value is 65.55, which has been above 60 for two consecutive days. Although it has not reached the overbought threshold, it suggests that the upward momentum may gradually weaken.

Bull case

  • Free cash flow continues to be positive (RMB 5.411 billion), the financial structure is solid, and it has strong risk resistance capabilities to support long-term growth logic.

Cautious view

  • At the time of writing, prices closed near all-time highs (52-week high $71.70), with retracement risks rising as technical indicators head towards overbought.
  • The PEG ratio is as high as 1.7, indicating that the current valuation has a high premium for earnings growth. If future growth is less than expected, it may trigger a valuation revision.
  • Although the current ratio (2.685) is good, the debt-to-equity ratio (1.424) is on the high side, and we need to pay attention to changes in debt costs and financing environment.

Risks

  • Policy level: If the speed of medical insurance integration is slower than expected, it may affect the efficiency of the realization of prescription circulation business.
  • Competitive landscape: Competition in the online pharmaceutical retail field has intensified, with competitors such as Alibaba Health and Ping An Good Doctor continuing to expand or shrink their market share.
  • Valuation risk: If PEG is higher than 1, if the company's actual profit growth slows down, it may lead to a valuation correction.
  • Financial risks: Despite ample free cash flow, a highly leveraged structure may increase interest burden during rising interest rate cycles.
  • Incident risk: If there are major customer complaints or supply chain management problems, it may cause fluctuations in public opinion and affect brand reputation.

Metrics to watch

  • Number of cities connected to medical insurance and settlement conversion rate: As a key verification indicator for the implementation of policy dividends, it directly affects the sustainability of the prescription drug business.
  • Non-pharmaceutical service revenue proportion and gross profit margin: Reflects the progress of the business model transformation from "traffic sales" to "health management services".
  • Monthly active user growth rate and user retention rate: core data for measuring platform stickiness and ecological operation capabilities.
  • Quarterly revenue and net profit year-on-year growth: After the release of the next quarter's financial report, it will determine whether the market's confidence in its growth path will continue.
  • Changes in Southbound Funds and Institutional Positions: Observe long-term fund trends and determine changes in the overall preference of foreign investors for the medical sector in Hong Kong stocks.

Regularly updated · want it fresher? Sign up for 3 free on-demand reports

US, Hong Kong and China ADR names alike. Understand what happened to a company recently and why — the decision is yours.

This page is research and explanation. It is not directed at any individual's investment decision and is not investment advice. Investing involves risk.

Related: China healthcare

Other research in the same sector and market, to put 6618.HK in context.

WuXi Biologics
2269.HK · China healthcare
Nongfu Spring
9633.HK · China consumer
Li Ning
2331.HK · China consumer
Haidilao
6862.HK · China consumer
CNOOC
0883.HK · China energy & utilities
China Shenhua
1088.HK · China energy & utilities
See all 150 stock research pages → · Research hub · Earnings briefs